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Abstract
Purpose To access frequency and severity of adverse
effects (AE) of non-hormonal drugs (NHD) for hot flashes
in breast cancer survivors compared to controls and ana-
lyze adverse-effect risk by reviewing published random-
ized trials.
Methods Cochrane Central Register for Controlled Trials,
Embase, Medline, PsycINFO and PubMed databases were
searched. Trials were included where participants were
survivors of breast cancer suffering from hot flashes,
treatment included self-administered venlafaxine, gaba-
pentin or clonidine, and AE were reported. AE frequency
and severity were graded. A meta-analysis of ten trials with
sub-group analyses was conducted.
Results Forty-nine studies were identified, and 12 were
included. A total of 1467 participants experienced 772
adverse effects, 81 % (n = 627) in the treatment group and
19 % (n = 145) in the control group. Sixty-seven percent
of AE was graded as mild and 33 % as moderate. The
frequency of AE for NHD was overall significant compared
to placebo. Sub-group analysis indicated that AE frequency
and severity increased at higher doses of venlafaxine and
gabapentin compared to placebo.
Conclusion The odds for experiencing AE was signifi-
cantly higher in patients randomized to high-dose NHD
than those randomized to controls, including placebo, low-
dose medication and acupuncture. These therapies should
be considered as a potential treatment alternative.
Keywords Adverse effects  Non-hormonal drugs 
Breast cancer  Hot flashes
Introduction
Breast cancer is the second most common cancer in the
world and the most frequent cancer among women. 1.67
million new cases were diagnosed in 2012 [1].
Treatment of breast cancer includes surgery, chemother-
apy, radiation and endocrine therapy. Fifty percent of
women diagnosed with breast cancer have a tumour that is
oestrogen receptor positive, and consequently, they are
offered hormone-suppression treatment lasting for at least
five years [2]. Tamoxifen is an oestrogen receptor modu-
lator which blocks the effect of oestrogen in breast tissue. It
is indicated for use in premenopausal women and, as an
initial treatment, in post-menopausal women. Aromatase
inhibitors are recommended only for post-menopausal
women, in whom the main source of oestrogen comes from
the conversion of testosterone to estradiol, facilitated by
the aromatase enzyme.
A common adverse effect of oestrogen-antagonist ther-
apy is hot flashes. Up to 80 % of women medicated with
tamoxifen suffer from hot flashes, 30 % of which rate them
as severe [3, 4]. Severe hot flash problems can result in
women stopping potentially lifesaving oestrogen-antago-
nist treatments; up to 25 % of women with breast cancer do
not adhere to adjuvant oestrogen-antagonist therapy [5].
Consequently, better management of adverse effects
& Jill Brook Hervik
jill.hervik@siv.no
1 Department of Anesthesia, Pain Clinic, Vestfold Hospital
Trust, 3116 Tonsberg, Norway
2 The National Research Center in Complementary and
Alternative Medicine (NAFKAM) Department of
Community Medicine, Faculty of Health Science, UiT The
Arctic University of Norway, 9037 Tromso, Norway
123
Breast Cancer Res Treat (2016) 160:223–236
DOI 10.1007/s10549-016-4002-x
including hot flashes is important for increasing compli-
ance and achieving optimal results.
Self-administered treatments for hot flash problems such
as drugs, creams or patches are the easiest and most
practical therapy for most women. The most effective
treatment is oestrogen therapy, but it is not recommended
in women with breast cancer, and no safe conclusions
regarding the use of progesterone are available [6]. Sixty
percent of breast cancer tumours are oestrogen and/or
progesterone receptor positive and therefore responsive to
hormonal influence [7]. Contraindications surrounding
hormonal therapies for the treatment of menopausal
symptoms in breast cancer survivors have provoked
increased use of non-hormonal drugs. Non-hormonal
treatment includes therapies that do not affect oestrogen or
progesterone production or action [8]. Self-administered
therapies including anti-hypertensive medications, selec-
tive serotonin reuptake inhibitors (SSRI), selective nore-
pinephrine reuptake inhibitors (SNRI), and anticonvulsant
medicines have been studied for hot flash symptoms and
increasingly used during the last decade. The most com-
monly used drugs in this category include venlafaxine, a
selective serotonin reuptake inhibitor; the anticonvulsant
gabapentin; and clonidine a centrally acting antiadrenergic
agent, commonly used to control hypertension.
Randomized controlled trials (RCT) of drugs in these
categories are limited; however, two systematic reviews
have reported on the efficacy of these three drugs as a
treatment for hot flashes in both breast cancer survivors and
healthy menopausal women [8, 9]. Paroxetine and Fluox-
etine, both being SSRIs, have also shown efficacy in the
reduction of hot flashes [10–13]; however, these drugs
interfere with the metabolization of tamoxifen to endoxifen
[10, 14] and are therefore contraindicated in women using
tamoxifen.
Various complementary and alternative therapies have
been studied as a treatment for HF in breast cancer patients.
Vitamin E has not demonstrated efficacy [8], while phy-
toestrogens possibly involve oestrogenic influence and are
therefore not recommended for women with breast cancer
[15]. Controversy around the safety of Cimicifuga Race-
mosa (Black Cohosh) as a treatment for menopausal
symptoms exists because of its purported oestrogenic
activity. A systematic review of 26 articles concluded that
current evidence does not support an association
between black cohosh and increased risk of breast cancer,
and those conflicting but promising results for the reduc-
tion of HF in breast cancer patients warrant the need for
further research [16]. Cognitive behavioural therapy trials
[17, 18] and relaxation [19] have shown modest, short-term
effect. Two trials investigating the effect of homoeopathy
versus placebo [8], neither were RCT, found a statistically
significant improvement in HF frequency for homoeopathy
over placebo. Acupuncture was as effective as venlafaxine
in a trial comparing these two interventions. However, 18
incidences of adverse effects were recorded in the ven-
lafaxine group, whereas the acupuncture group experienced
no adverse effects [20]. A systematic review of acupunc-
ture to control hot flashes, which included 8 breast cancer
studies (n = 474), concluded that the current level of
evidence is insufficient to support the treatment of hot
flashes [21].
The importance of this review
The efficacy and adverse-effect profiles of hot flash treat-
ment vary in non-hormonal pharmacological interventions.
Comparing studies of interventions in this category may
provide an indication as to whether treatment effect out-
weighs adverse effects in breast cancer survivors. Potential
information regarding the tolerability of each drug has
direct clinical implications, affecting decision making and
compliance.
Aims
The aims of this review are to
1. systematically investigate how adverse effects of the
three most commonly used non-hormonal drugs, to
treat hot flashes in breast cancer patients, are reported
in randomized controlled trials;
2. classify adverse effects and drug-related aggravations
according to the Common Terminology Criteria for
Adverse Effects (CTCAE) [22] and
3. perform a meta-analysis to evaluate the risk of adverse
effects for patients pharmacologically managing their
hot flashes with non-hormonal self-administered ther-
apy, compared to different controls.
Terminology
If a substance is capable of producing a therapeutic effect,
it can also produce harmful or unwanted effects. Terms
used to describe such unwanted effects include side effect,
adverse effect, adverse event, adverse reaction and toxic
effect [23]. The term adverse effect used in this paper is
defined by The European Medicines Agency [24] as any
untoward medical occurrence in a patient or clinical trial
subject administered a medical product. This term
encompasses all unwanted effects, without making
assumptions about their mechanism [25].
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Methods
Search methods for identification of studies
The focus question was: Are the most commonly used non-
hormonal drugs for hot flashes in breast cancer patients
associated with adverse effects? The four elements from
PICO were used when searching for relevant articles:
1. Population: Patients with breast cancer, suffering from
hot flashes.
2. Intervention: Non-hormonal self-administered pharma-
cological therapies, including venlafaxine, gabapentin
and clonidine.
3. Comparison: Placebo, other non-hormonal drugs, con-
ventional medical therapies, CAM, waiting list and
usual care.
4. Outcome: Adverse effects, adverse events, adverse
reactions, tolerability, side effects and toxicity.
The following electronic databases were searchedwith no
language, publication, or time restrictions: Cochrane Central
Register for Controlled Trials (Central) in the Cochrane
library, Embase, Medline, PsycINFO and PubMed.
Titles and abstracts were identified through the search
strategy. If no abstract was available, the full text paper
was obtained for inspection. Both authors did the searches,
read the articles and extracted the data (search strings are
attached in the appendix). Grey literature was searched in
order to find possibly missed articles through electronic
searches. References of all retrieved articles and systematic
reviews were searched [8, 9, 26–28]. Depending on the
database, various combinations of MESH terms and key-
words were used. MESH terms included breast neoplasms,
breast cancer, hot flashes, clonidine, adverse effect,
adverse drug reaction reporting systems. The following
keywords were applied: breast cancer, hot flash, hot flush,
vasomotor symptom, clonidine, venlafaxine, gabapentin,
adverse effect, adverse event and side-effect.
Inclusion comprised randomized controlled trials that
reported adverse effects of treatment. Both parallel group
design and cross-over studies were included. Data from
cross-over studies were included from both treatment
periods, since all cross-over studies specified that there was
no cross-over effect.
Data were extracted to give information on the total
number of adverse effects and number of patients experi-
encing the adverse effects. Severity of adverse effects was
assessed using the CTCAE grading system and was entirely
dependent on the information provided in the articles. The
system grades adverse effects from 1 to 5, where 1 indi-
cates mild symptoms, 2 moderate symptoms, 3 severe
symptoms, 4 life threatening and 5 fatal symptoms. When
summarizing the data, the total number of adverse effects
was counted, regardless of the number of participants
experiencing them. Both authors categorized and graded
the data. Lack of consensus was settled by discussion.
A methodological assessment including risk of bias was
made by both authors using criteria from the Cochrane
Handbook of Systematic Reviews and Interventions [29].
The trials were rated as follows:
A grading of ‘‘A’’ indicates a RCT of high quality with
low risk of bias with adequate measures to conceal allo-
cation, detailed randomization description and implemen-
tation of the intention to treat principle.
Grade ‘‘B’’ was used when method of allocation con-
cealment was not described, or was unclear, creating a
moderate risk of bias.
A grade ‘‘C’’ was used when the method of allocation
was not concealed; such trials were excluded because of
high risk of bias.
Extracted data included number of patients randomized
to each group, number of dropouts, use of power calcula-
tion, whether the intention to treat principle was followed,
intervention (including dose), duration of intervention,
main findings and funding. The authors of retrieved articles
were contacted when in doubt of or there is a lack of
information in the publications (Table 1).
Meta-analysis
Study populations were divided into groups experiencing
adverse effects versus those with no adverse effects in both
treatment and control groups. Homogenous study designs
including participants, interventions, control groups and
outcome measures were combined and a meta-analysis
performed; P\ 0.10 defined significant heterogeneity.
Odds ratios and 95 % confidence intervals were calculated
from the number of patients experiencing adverse effects in
each group based on the total number of patients ran-
domized to either treatment or control group. Studies with
no adverse effects either in one or both groups were given
an added continuity correction of 0.5 in order to estimate a
valid approximation of odds ratio [30]. Data regarding the
adverse effect in a trial carried out by Boekhout, which
compared venlafaxine and clonidine to placebo, were
found to be identical for both the venlafaxine and clonidine
groups [31]. These data were included only once in the
meta-analysis to avoid overrepresentation of adverse
effects in the intervention group. Three studies comparing
different drug dosages to placebo were divided according
to high and low dosage in the meta-analysis [32–34]. Based
on the total number of participants randomized to the
treatment or control group, odds ratios and 95 % confi-
dence intervals were calculated from the number of
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patients experiencing adverse effects in each group. To
perform a meta-analysis, data were entered directly from
the datasheets into Review Manager 5 computer program
[35].
Results
Outcome of the literature searches
A total of 49 articles were identified. They were initially
examined on the basis of titles and abstracts; 37 were
excluded from further examination due to the following: 30
did not meet inclusion criteria and seven were multiple
article registrations in databases. A total of 12 articles were
included in this review (Fig. 1).
The control intervention was clonidine in three studies
[31, 37, 39] and placebo in five studies. These five studies
compared venlafaxine, or clonidine, or gabapentin to pla-
cebo [32–34, 37, 38]. Two of these studies examined
venlafaxine at two [32] and three [33] different doses and
one study examined gabapentin at two different doses [34].
Three studies compared gabapentin to other therapies:
vitamin E [39], hypnotherapy [40] and electro-acupuncture
[41], and one compared venlafaxine to acupuncture [20].
Methodological assessment as described in the
Cochrane handbook was used to rate the included trials: All
were classified as high quality (A), apart from three RCTs
in which risk of bias was increased by providers and par-
ticipants not being blinded [20, 39] and one where no
blinding was used and the sample size was small [40].
Five studies included more than one active treatment
arm [31–34, 41]. Four studies had a cross-over design
[32, 36, 38, 42]. Number of participants ranged from a
minimum of 27 to a maximum of 420. The duration of the
studies ranged from 4 to 24 weeks.
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Types of adverse effects were reported in all the inclu-
ded studies. Number of patients suffering from adverse
effects and number of adverse effects were reported in all
but two studies [32, 38] where specific adverse effects were
compared to placebo and reported as p values. We tried to
contact the authors of these two studies in order to gain
access to more comparable data. We were not able to get in
touch with Goldberg; Carpenter kindly provided more data,
but the actual numbers concerning adverse effects were not
available. These two studies were consequently excluded
from the meta-analysis. One study presented data on
adverse effects only if these were the reason for dropping
out, possibly causing an underestimation of the number of
adverse effects [34]. A total of 1467 participants experi-
enced 772 adverse effects. Of these, 81 % (n = 627) were
in the treatment group and 19 % (n = 145) were in the
control group. Adverse effects included appetite disorder,
nausea, dry mouth, fatigue, dizziness, headache, difficulty
sleeping, anxiety, memory problems, sweating, constipa-
tion, double vision and increased blood pressure.
Sixty-seven percent of the adverse effects were graded
as CTCAE I (n = 515) and 33 % were graded as
CTCAE II (n = 257) (Table 2). Adverse effects causing
participants to dropout were classified as CTCAE grade
II.
Whether dropping-out in the included studies was due to
adverse effects was reported in all but four studies
[33, 34, 38, 41]. In the three studies comparing venlafaxine
and clonidine, the number of dropouts due to adverse
effects were fourteen and five [36], six and four [42] and
six and two [31], respectively, totalling 26 in the ven-
lafaxine groups versus 11 in the clonidine groups. Gaba-
pentin was compared to placebo [34], hypnotherapy [40]
and vitamin E [39], where sixteen, three and seventeen
women, respectively, dropped out of the gabapentin groups
due to adverse effects; there were no dropouts in the second
arms. Venlafaxine was compared to placebo [32], where
the number of dropouts were 3 versus 1, and acupuncture
[20], where the only dropouts due to adverse effects were 3
women in the venlafaxine group.
Fig. 2 Forest Plot
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Meta-analyses
Adverse effects’ data from 10 RCTs were included in the
meta-analysis with a total of 1,428 subjects.
Non-hormonal medication versus overall control
An overall comparison was made between non-hormonal
medication and control. Ten trials had 13 different out-
comes due to low and high drug doses in the same trials. A
significant difference was found between non-hormonal
medication and control, with OR of 1.67, 95 % CI of
1.31–2.13 and I2 of 85 % (P\ 0.0001).
Different sub-group meta-analyses according to the
categories of controls were performed, and are presented
below.
Non-hormonal medication versus placebo
A comparison was made between non-hormonal medica-
tion and placebo. Two trials (259 participants) made this
comparison, and a statistically significant difference was
found between non-hormonal medication and placebo, with
OR of 1.51, 95 % CI of 1.16–1.98 and I2 of 0 %
(P = 0.002).
High-dose non-hormonal medication versus placebo
There was no statistically significant difference between
high-dose non-hormonal medication and placebo in a meta-
analysis of two trials (n = 450) for three different com-
bined outcomes, with OR of 2.96, 95 % CI of 0.97–9.05
I2 and 93 % (P = 0.06).
Low-dose non-hormonal medication versus placebo
A comparison was made between low-dose non-hormonal
medication and placebo. Two trials (345 participants) made
this comparison, and no statistically significant difference
was found between the groups (OR 1.53, 95 % CI
0.62–3.77, I2 = 87 %, P = 0.36).
Non-hormonal medication versus non-hormonal
medication
There was a significant difference between non-hormonal
medication (venlafaxine) and non-hormonal medication
(clonidine) in a meta-analysis of two trials, with OR of
1.44, 95 % CI of 1.00–2.08 and I2 of 45 % (P = 0.05).
Non-hormonal medication versus acupuncture
A comparison was made between non-hormonal medica-
tion and acupuncture. Two trials (108 participants) made
this comparison; a significant difference was found
between the groups in favour of acupuncture, with OR of
1.75, 95 % CI of 01.09–2.75 and I2 of 0 % (P = 0.02).
Non-hormonal medication versus other therapy
There was no statistically significant difference between
non-hormonal medication and other therapies in a meta-
analysis of two trials, with OR of 1.34, 95 % CI of
0.74–2.45 and I2 of 34 % (P = 0.33).
Discussion
This meta-analysis demonstrated that the odds for experi-
encing adverse effects was significantly higher in patients
randomized to non-hormonal medication than for patients
randomized to controls, such as placebo and acupuncture.
High-dose non-hormonal medication (venlafaxine and
gabapentin) provoked an increased number of adverse
effects compared to low-dose medication. This may sug-
gest that low-dose non-hormonal medication is a good
alternative for breast cancer survivors with hot flashes,
providing sufficient reduction in frequency and intensity of
hot flashes. Rada et al. [8] in their systematic review report
that non-hormonal therapies have a mild to moderate effect
in reducing frequency and intensity of hot flashes in
women with a history of breast cancer. This result was
based on nine different studies evaluating the effect of
SSRIs (n = 6), clonidine (n = 2) and gabapentin (n = 1).
Acupuncture has few adverse effects compared to non-
hormonal medication and should be considered as a
potential treatment alternative if efficacy can be confirmed
in future studies. Four systematic reviews evaluating
acupuncture for hot flashes in breast cancer survivors
included six [44], seven [43], eight [21] and twelve [45]
RCT’s respectively. Overall, authors concluded that
acupuncture effectively reduced hot flashes, but was not
statistically significant compared to sham; and that there is
currently insufficient evidence to either support or refute
acupuncture for this patient category.
Twelve trials were identified for this systematic review,
and ten of these were included in the meta-analysis. We
pooled results in an attempt to give an overall comparison
of non-hormonal medication versus control; six different
sub-group analyses were done. However, only two trials
made up each group, thereby only demonstrating
tendencies.
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Study strengths and limitations
As far as we know, this is the first systematic review and
meta-analysis to examine adverse effects of non-hormonal
medications for hot flashes in breast cancer survivors, as
the primary outcome measure. The included studies were
of high methodological quality and with reduced risk of
bias, thereby providing reliable results. Heterogeneity is
always an important consideration when compared to
RCTs, and the forest plot showed strong study similarities.
Two-thirds of adverse effects reported in this review
were classified as grade I and a third as grade II. The
CTCAE grading of adverse effects was solely based on
information provided by the articles included in this
review, and should be considered as an approximation of
adverse effect severity. Inconsistent use of safety termi-
nology made it difficult to categorize and evaluate the data;
the CTCAE grading system was not consistently used.
Three different non-hormonal medications were asses-
sed and compared to different control groups. This was a
limiting factor in the meta-analysis. To reduce the risk of
inflating the size of the pooled treatment effect, zero-cell
counts were included [46]. A continuity correction of 0.5
was used for studies with zero-cell counts, in order to
provide a conservative approximation of adverse event risk
[47].
Six studies included in the meta-analysis had active
controls, including other non-hormonal medicines,
acupuncture and other therapies, possibly inflating adverse-
effect frequency outcomes; however, the forest plot
(Fig. 2) does not indicate such influence when studies with
active controls are compared to those with passive controls.
Other elements of conceivable bias include possible
under-reporting of adverse effects by participants moti-
vated to experience treatment effect, simply due to being
included in a clinical trial. Publication bias is also a con-
sideration; clinical trials demonstrating a statistically sig-
nificant treatment effect compared to control are more
likely to be published [48].
Search strategy for this review included five search
engines, and more RCTs may have been identified if more
search engines had been added. However, we also identi-
fied a systematic review focusing on active interventions
for hot flash symptoms in breast cancer patients [8] and 4
reviews focusing on a combination of post-menopausal
women and breast cancer survivors [9, 26–28]. Examina-
tion of the full texts and reference lists of these reviews did
not provide any additional RCTs for this meta-analysis.
Other studies
To our knowledge, only one systematic review evaluating
non-hormonal therapies for hot flashes in women with a
history of breast cancer has been published, and the focus
was on treatment efficacy [8]. We could not find any sys-
tematic reviews that examined adverse effects due to non-
hormonal drugs as a primary outcome in this patient cat-
egory. Rada and colleagues reported evidence supporting
the use of clonidine, gabapentin and SSRIs/SNRIs for hot
flash symptoms in breast cancer survivors. The authors
commented that adverse effects were inconsistently
reported. 16 studies were included, of which 10 were
pharmacological studies and 6 non-pharmacological stud-
ies. They confirmed our findings that adverse effects
increase when higher doses of gabapentin and venlafaxine
were used. They also suggested that adverse effects may
outweigh benefit in clonidine.
Another systematic review of 13 randomized trials com-
paring active interventions for hot flash problems in women
with and without breast cancer [26] did not agree with our
findings of dose-related increased frequency of adverse
effects. The authors reported that high doses of venlafaxine
(75 mg/day) and gabapentin (900 mg/day) appeared to
improve hot flash symptoms to a greater extent compared to
lower doses, without incurring more adverse effects. Since
the population did not only include breast cancer patients, the
results make comparison with our study difficult.
Implications
Despite these limitations, the sub-group analyses provided
information relevant for clinical practice, including the
relationship between drug dosage and adverse effects, drug
comparisons in relation to adverse effects and the possible
role of acupuncture as a treatment for hot flashes if efficacy
can be confirmed. Further research is indicated to investi-
gate these findings with focus on efficacy versus adverse
effects; also the effect of combined therapies should be
considered with a view to increasing the compliancy of
oestrogen-antagonist medication.
Conclusion
The odds for experiencing adverse effects was statistically
significantly higher in patients randomized to high-dose
non-hormonal medication than for patients randomized to
controls, such as placebo, low-dose medication and
acupuncture. Consequently, these therapies should be
considered as a potential treatment alternative if efficacy
for hot flushes can be confirmed.
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